Brief: Ose Immunotherapeutics Updates On Cancer Vaccine Tedopi

Ose Immunotherapeutics SA

20/10/2022 17:12

Oct 20 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS UPDATES ON TEDOPI®, A CANCER
VACCINE AS
POTENTIAL NEW STANDARD OF CARE IN NON-SMALL CELL LUNG CANCER
AFTER FAILURE TO IMMUNOTHERAPIES
    * REGULATORY MEETINGS ARE PLANNED TO VALIDATE THE
CONFIRMATORY
PHASE 3 CLINICAL TRIAL IN NSCLC
    * HAS FILED A FORMAL REQUEST FOR A “TYPE C MEETING” WITH THE
US
FOOD AND DRUG ADMINISTRATION (FDA) TO VALIDATE THE NEW STUDY
PROTOCOL IN NSCLC METASTATIC PATIENTS IN SECOND LINE AFTER
ICI-FAILURE

Source text for Eikon:  ID:nNDL5c9Jjh 
Further company coverage:  OSE.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))